As a second-generation cyclin-dependent kinase (CDK) inhibitor, AT7519 suppresses human glioblastoma cell growth via the caspase-3/GSDME-mediated pyroptotic pathway, suggesting that AT7519 is a potential GBM treatment chemical agent [144]. This evidence concerns the gene GSDME and glioblastoma.